Nervous System Diseases

1,005 trials 421 recruiting

Filter these 1,005 trials by phase, country and sponsor.

Open in Search →

The ExPlas Study Ended

2024-518668-11-01 Early symptomatic phase Alzheimer's disease 4 2021-09-17
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS) Ended

2023-505641-12-00 Amyotrophic Lateral Sclerosis (ALS) associated with SOD 5 2021-07-27
AHEAD 3-45 Study: A Clinical Study to Investigate the Effects of BAN2401 in Subjects With Preclinical Alzheimer’s Disease Ended

2024-510888-39-00 Early Preclinical Alzheimer’s Disease and Intermediate 5 2021-07-21
Proof-of-concept study for SAR441344 (frexalimab) in relapsing multiple sclerosis. Ended

2024-513527-17-00 Multiple Sclerosis 4 2021-06-07
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Ended

2023-507132-21-00 Early Parkinson's disease 10 2021-05-11
Non-inferiority study of ocrelizumab and rituximab in active multiple sclerosis Ended

2024-514287-84-00 Multiple sclerosis 5 2021-04-28
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine ( REBUILD-2 ) Ended

2023-505835-11-00 Chronic Migraine 5 2021-03-12
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine ( REBUILD-1 ) Ended

2023-505836-36-00 Migraine 5 2021-03-12
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
An extension study to learn if bepranemab (UCB0107) is safe over a long period in adults with progressive supranuclear palsy Ended

2024-510951-36-00 Progressive Supranuclear Palsy 3 2020-11-16
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended

2024-510716-71-00 Multiple Sclerosis 5 2020-10-21
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
CLINICAL TRIAL WITH MESENCHYMAL STEM CELLS IN STROKE PATIENTS Ended

2024-512514-18-00 ISCHEMIC STROKE 4 2020-09-17
N/A Ended

2024-513086-39-00 Spinal Muscular Atrophy 5 2020-06-16
An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Ended

2024-516680-91-00 relapsing multiple sclerosis 5 2020-05-21
A clinical study to investigate the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral trea… Ended

2024-511940-20-00 Parkinson's disease 5 2020-02-05
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Ocrelizumab in Children and Adolescents with Rela… Ended

2023-507313-94-00 Relapsing-Remitting Multiple Sclerosis (RRMS) 4 2019-10-18
A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended

2024-510887-22-00 Mild cognitive impairment due to Alzheimer's disease or 5 2019-09-30
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19
Study to compare the efficacy and safety of NT 201 (botulinum toxin) with placebo for the treatment of lower limb spasticity caused by strok… Ended

2023-505810-12-00 Lower limb spasticity 5 2019-09-03
Effect of cladribine treatment on microglial activation in the CNS Ended

2024-519921-39-00 Multiple Sclerosis 6 2019-08-16
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon beta-1a) in Pediatric Participants for the Treatment of… Ended

2023-505624-56-00 Relapsing Remitting Multiple Sclerosis (RRMS) 5 2019-08-07
Efficacy and Safety of Erenumab in Pediatric Subjects with Episodic Migraine Ended

2023-504930-23-00 Episodic Migraine 5 2019-07-19